Cardiovascular Drugs Practice Questions

Q: Which of the following statements is not true regarding the use of clonidine in the treatment of hypertension?

Increases LDL-cholesterol with prolonged use.. Clonidine is a centrally acting antihypertensive agent. The correct answer is **B** because clonidine is **metabolically neutral**; it does not adversely affect lipid profiles (LDL, HDL, or triglycerides) or glucose metabolism, making it safe for patients with dyslipidemia or diabetes. ### **Explanation of Options:** * **Option A (True):** Clonidine is a selective **$\alpha_2$-adrenergic agonist** in the nucleus tractus solitarius of the medulla. Stimulation of these receptors inhibits the vasomotor center, leading to a reduction in central sympathetic outflow and a decrease in blood pressure. * **Option B (False/Correct Answer):** As stated, clonidine has no significant effect on plasma lipids. This is a high-yield distinction from older diuretics or non-selective beta-blockers which may alter lipid profiles. * **Option C (True):** Due to its central action and inhibition of salivary secretions, **sedation** and **xerostomia** (dry mouth) are the most frequently reported side effects, occurring in up to 50% of patients. * **Option D (True):** Clonidine can be combined with vasodilators (like hydralazine). Vasodilators often cause reflex tachycardia; clonidine helps counteract this by reducing sympathetic tone. ### **High-Yield Clinical Pearls for NEET-PG:** * **Rebound Hypertension:** Sudden withdrawal of clonidine can cause a hypertensive crisis due to a massive surge in catecholamines. It must be tapered slowly. * **Treatment of Rebound HTN:** Managed with a combination of $\alpha$ and $\beta$ blockers (e.g., Phentolamine + Propranolol) or Labetalol. * **Other Uses:** Clonidine is also used in opioid withdrawal, ADHD, Tourette syndrome, and hot flashes.

Q: ACE inhibitors are contraindicated in all of the following conditions except:

Diabetes. **Explanation:** ACE inhibitors (ACEIs) are the **drugs of choice** for patients with **Diabetes Mellitus**, especially those with diabetic nephropathy. This is because they exert a Reno-protective effect by dilating the efferent arteriole, thereby reducing intraglomerular pressure and decreasing proteinuria. **Why the other options are contraindicated:** * **Pregnancy (Option A):** ACEIs are absolute contraindications (Teratogenic). They interfere with fetal kidney development, leading to oligohydramnios, fetal renal failure, and skull hypoplasia. * **Bilateral Renal Artery Stenosis (Option C):** In this condition, glomerular filtration rate (GFR) is maintained by Angiotensin II-mediated vasoconstriction of the efferent arteriole. ACEIs block this mechanism, leading to a precipitous drop in GFR and acute renal failure. * **Renal Failure (Option D):** While ACEIs are used in early chronic kidney disease, they are generally contraindicated in advanced renal failure or acute kidney injury, particularly if serum creatinine is >3 mg/dL or if there is pre-existing hyperkalemia, as ACEIs further increase potassium levels. **NEET-PG High-Yield Pearls:** 1. **Side Effects:** The most common side effect is a **dry cough** (due to increased Bradykinin); the most serious is **Angioedema**. 2. **Drug of Choice:** ACEIs are first-line for Hypertension in patients with Diabetes, Heart Failure, and post-Myocardial Infarction. 3. **Monitoring:** Always monitor Serum Potassium and Creatinine levels within 1-2 weeks of starting therapy.

Q: All of the following statements regarding niacin-induced flushing and pruritus are true EXCEPT?

Warrants immediate stoppage of niacin.. ### Explanation **Core Concept:** Niacin (Vitamin B3), used in high doses to treat dyslipidemia, commonly causes **cutaneous flushing and pruritus**. This is a well-known, dose-dependent side effect mediated by the release of **Prostaglandin D2 (PGD2) and PGE2** in the skin, leading to vasodilation. **Why Option C is the Correct Answer (The False Statement):** Flushing is a **benign, self-limiting side effect** and does not indicate drug toxicity or an allergic reaction. Therefore, it **does not warrant immediate stoppage** of the medication. Most patients develop tolerance to this effect within 1–2 weeks of continued therapy. **Analysis of Incorrect Options:** * **Option A:** Niacin binds to G protein-coupled receptors (GPR109A) on dermal macrophages and keratinocytes, triggering the release of **prostaglandins**. This is the primary mechanism of flushing. * **Option B:** Ethanol is a vasodilator. Consuming **alcohol** or hot beverages alongside niacin exacerbates cutaneous vasodilation, making flushing more severe. * **Option C:** Since the mechanism is prostaglandin-mediated, taking **Aspirin (325 mg)** or other NSAIDs 30 minutes before the niacin dose significantly reduces the severity of flushing. --- ### High-Yield Clinical Pearls for NEET-PG: * **Mechanism of Niacin in Dyslipidemia:** It inhibits adipose tissue lipolysis (via hormone-sensitive lipase inhibition), leading to decreased VLDL and LDL, and is the most potent agent for **increasing HDL**. * **The "Niacin Flush" Prevention:** Start with low doses, take with meals, avoid hot/alcoholic drinks, and pre-treat with **Aspirin**. * **Other Side Effects:** Hyperuricemia (can precipitate **Gout**), Hyperglycemia (caution in Diabetics), and Hepatotoxicity. * **Hartnup Disease:** A deficiency of Tryptophan transport leading to Niacin deficiency (Pellagra-like symptoms: Dermatitis, Diarrhea, Dementia).

Q: When treating hypertension chronically, orthostatic hypotension is maximum with which of the following medications?

Guanethidine. Guanethidine is the correct answer because it is a potent adrenergic neuron blocker. It works by inhibiting the release of norepinephrine from postganglionic sympathetic nerve endings and depleting catecholamine stores [1]. By profoundly blocking sympathetic outflow, it prevents the compensatory vasoconstriction that normally occurs upon standing. This leads to a severe drop in blood pressure, making orthostatic (postural) hypotension its most characteristic and dose-limiting side effect [1], [3]. **Analysis of Incorrect Options:** * **Clonidine (A):** An alpha-2 agonist that acts centrally to reduce sympathetic outflow. While it causes sedation and dry mouth, it rarely causes significant orthostatic hypotension because it does not completely paralyze peripheral sympathetic reflexes [2]. * **Prazosin (C):** A selective alpha-1 blocker. It is notorious for the **"first-dose phenomenon"** (severe syncope after the initial dose), but with chronic use, the risk of orthostatic hypotension is significantly less than that of Guanethidine. * **Propranolol (D):** A non-selective beta-blocker. It reduces blood pressure primarily by decreasing cardiac output and renin release. It does not interfere with alpha-mediated vasoconstriction; therefore, orthostatic hypotension is not a typical side effect. **High-Yield Clinical Pearls for NEET-PG:** * **Guanethidine** is rarely used today due to its side effect profile, which includes **explosive diarrhea** and **retrograde ejaculation**. * **Tricyclic Antidepressants (TCAs)** can block the uptake of Guanethidine into the neuron, thereby reversing its antihypertensive effect [1]. * **Rule of Thumb:** Drugs that interfere with peripheral sympathetic transmission (Guanethidine, Alpha-blockers) cause more orthostatic hypotension than those acting centrally (Clonidine) or on the heart (Beta-blockers).

Q: A 55-year-old man presents with erectile dysfunction and is prescribed sildenafil. He reports a marked improvement in his ability to sustain an erection with this treatment. The action of which of the following vasoactive mediators would primarily be prolonged in this patient?

Nitric Oxide. ### Explanation **Correct Option: D. Nitric Oxide** The physiological process of penile erection is mediated by the release of **Nitric Oxide (NO)** from parasympathetic nerve endings (nervi erigentes) and vascular endothelial cells [1]. NO activates the enzyme **guanylate cyclase**, which converts GTP into **cyclic Guanosine Monophosphate (cGMP)** [1]. cGMP acts as a second messenger that causes smooth muscle relaxation in the corpus cavernosum, leading to increased blood inflow. **Sildenafil** is a selective inhibitor of **Phosphodiesterase type 5 (PDE-5)**, the enzyme responsible for degrading cGMP. By inhibiting PDE-5, sildenafil prevents the breakdown of cGMP, thereby prolonging the vasodilatory action initiated by Nitric Oxide [1]. **Analysis of Incorrect Options:** * **A. Histamine:** While histamine can cause vasodilation, it is not the primary mediator of the erectile response and is not targeted by PDE-5 inhibitors. * **B. Endothelin-1:** This is a potent **vasoconstrictor**. Increased levels would oppose an erection rather than facilitate it. * **C. Prostacyclin (PGI2):** Although prostacyclin causes vasodilation via the cAMP pathway, sildenafil specifically targets the cGMP pathway associated with Nitric Oxide. **High-Yield Clinical Pearls for NEET-PG:** * **Innervation:** Parasympathetic fibers (S2–S4) via the **pelvic splanchnic nerves** are responsible for erection ("Point"), while Sympathetic fibers (T11–L2) are responsible for ejaculation ("Shoot"). * **Drug Interaction:** Sildenafil is strictly contraindicated in patients taking **Nitrates** (e.g., Nitroglycerin) because both increase cGMP, leading to life-threatening hypotension [2]. * **Site of Action:** PDE-5 is found predominantly in the **corpus cavernosum** and **pulmonary vasculature** (hence sildenafil's use in Pulmonary Arterial Hypertension).

Q: Alirocumab and Evolocumab are classified as which of the following?

PCSK-9 inhibitors. ### Explanation **Correct Option: C. PCSK-9 inhibitors** Alirocumab and Evolocumab are monoclonal antibodies that inhibit **Proprotein Convertase Subtilisin/Kexin type 9 (PCSK-9)**. * **Mechanism:** Normally, PCSK-9 binds to LDL receptors (LDLR) on the surface of hepatocytes and promotes their degradation. By inhibiting PCSK-9, these drugs increase the recycling and density of LDL receptors on the liver cell surface. * **Result:** Increased LDLRs lead to enhanced clearance of LDL-cholesterol from the plasma, resulting in a significant reduction (up to 60%) in LDL levels. **Why other options are incorrect:** * **A. NPGL1 inhibitors:** This likely refers to **Ezetimibe**, which inhibits the Niemann-Pick C1-Like 1 (NPC1L1) protein. It acts by blocking the intestinal absorption of dietary and biliary cholesterol. * **B. Microsomal transport protein (MTP) inhibitors:** The prototype drug is **Lomitapide**. It prevents the assembly of apoB-containing lipoproteins (VLDL and chylomicrons) in the liver and intestine. * **D. Lipoprotein lipase (LPL) inhibitors:** This is physiologically counterproductive for treating lipid disorders. Drugs like **Fibrates** actually *stimulate* LPL activity to enhance the clearance of triglyceride-rich lipoproteins. **High-Yield Clinical Pearls for NEET-PG:** * **Route of Administration:** These are administered as **subcutaneous injections** once every 2–4 weeks. * **Indications:** Used in patients with **Familial Hypercholesterolemia** or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional LDL lowering despite maximally tolerated statin therapy. * **Side Effects:** Generally well-tolerated; most common side effects are injection site reactions and nasopharyngitis. * **Bempedoic Acid (Newer Drug):** Often tested alongside these; it inhibits **ATP citrate lyase**, acting upstream of HMG-CoA reductase.

Q: In which condition is Digoxin indicated for Congestive Heart Failure (CHF)?

Atrial fibrillation with a high ventricular rate. **Explanation:** Digoxin is a cardiac glycoside that exerts two primary effects: **positive inotropy** (by inhibiting Na+/K+ ATPase) and **negative chronotropy/dromotropy** (via vagomimetic action on the AV node). **Why Option C is Correct:** In patients with Congestive Heart Failure (CHF) and concomitant **Atrial Fibrillation (AF)**, Digoxin is highly effective. Its vagomimetic action slows conduction through the Atrioventricular (AV) node, thereby reducing the ventricular rate. This allows for better diastolic filling and improved cardiac output, making it a preferred choice for rate control in heart failure patients. **Why Other Options are Incorrect:** * **A. Hypertrophic Obstructive Cardiomyopathy (HOCM):** Digoxin is **contraindicated**. Increasing contractility (positive inotropy) in HOCM worsens the outflow tract obstruction, potentially leading to sudden cardiac collapse. * **B. High Output Failure:** Conditions like anemia, thyrotoxicosis, or thiamine deficiency cause heart failure due to excessive demand rather than primary pump failure. Digoxin is generally ineffective here as the underlying cause is metabolic or systemic, not a lack of contractility. **High-Yield NEET-PG Pearls:** * **Mechanism:** Inhibits Na+/K+ ATPase → increased intracellular Na+ → decreased Na+/Ca2+ exchange → increased intracellular Ca2+ → increased contractility. * **ECG Changes:** Characterized by the "reverse tick" or "Salvador Dali mustache" sign (ST-segment depression). * **Toxicity:** Hypokalemia predisposes to Digoxin toxicity. The most common arrhythmia in toxicity is **Ventricular Bigeminy**, while the most characteristic is **Non-paroxysmal Atrial Tachycardia with AV block**. * **Antidote:** Digibind (Digoxin-specific Fab fragments).

Q: Amyl nitrate is used by which route?

Inhalation. **Explanation:** **Amyl Nitrite** is a highly volatile liquid vasodilator belonging to the organic nitrate class. The correct route of administration is **Inhalation** because the drug is supplied in thin glass ampoules (crushable "pearls") wrapped in protective fabric. When crushed, the liquid vaporizes instantly and is inhaled through the nostrils, leading to rapid absorption across the pulmonary alveolar-capillary membrane. **Why the other options are incorrect:** * **Oral:** Amyl nitrite undergoes extensive **first-pass metabolism** in the liver, making oral administration ineffective. Furthermore, its rapid onset of action (within 30 seconds) is required for its clinical uses, which oral ingestion cannot provide. * **Intravenous:** While other nitrates like Nitroglycerin can be given IV, Amyl nitrite is specifically formulated for inhalation. IV administration is not standard due to the difficulty in titrating its extremely rapid and short-lived effect. * **Intramedullary:** This route (into the bone marrow) is reserved for emergency fluid resuscitation when IV access is impossible; it has no role in nitrate therapy. **Clinical Pearls for NEET-PG:** 1. **Mechanism in Cyanide Poisoning:** Amyl nitrite is a rapid-acting inducer of **Methemoglobinemia**. Methemoglobin has a high affinity for cyanide, forming **Cyanmethemoglobin**, which prevents cyanide from binding to Cytochrome Oxidase. 2. **Diagnostic Use:** In cardiology, it is used to differentiate heart murmurs. It **increases** the intensity of the murmur in **HOCM** and Mitral Regurgitation (due to decreased afterload) but decreases the murmur of Aortic Stenosis. 3. **Side Effects:** The most common side effect is a "throbbing" headache and orthostatic hypotension.

Q: In congestive cardiac failure, all of the following are used EXCEPT:

Trimetazidine. ### Explanation **Correct Answer: D. Trimetazidine** **1. Why Trimetazidine is the correct answer:** Trimetazidine is a **metabolic modulator** that inhibits the enzyme **3-ketoacyl-CoA thiolase (3-KAT)**. This shifts myocardial metabolism from fatty acid oxidation to glucose oxidation, which is more oxygen-efficient. While it is an effective **anti-anginal drug** used for chronic stable angina, it has no established role in the standard management of Congestive Cardiac Failure (CCF). It does not improve hemodynamics or mortality in heart failure patients. **2. Why the other options are used in CCF:** * **A. Spironolactone:** An aldosterone antagonist (MRA) that is a cornerstone of heart failure therapy. It prevents myocardial fibrosis and remodeling, significantly reducing mortality in patients with HFrEF (NYHA Class II-IV). * **B. Nitrates:** These are vasodilators. In acute heart failure, they reduce **preload** (venous dilation), relieving pulmonary congestion. In chronic cases, they are often combined with Hydralazine to reduce mortality, especially in specific populations. * **C. Nesiritide:** A recombinant form of **B-type Natriuretic Peptide (BNP)**. It causes vasodilation and natriuresis, used primarily in acute decompensated heart failure to reduce dyspnea and wedge pressure. **3. High-Yield Clinical Pearls for NEET-PG:** * **Drugs reducing mortality in CCF:** Beta-blockers (Carvedilol, Metoprolol, Bisoprolol), ACE inhibitors/ARBs, ARNIs (Sacubitril/Valsartan), Spironolactone, and SGLT2 inhibitors (Dapagliflozin). * **Trimetazidine Side Effect:** Can cause **Parkinsonian symptoms** (tremors, rigidity) and should be avoided in patients with Parkinson’s disease. * **Nesiritide** is contraindicated in patients with cardiogenic shock or systolic BP < 90 mmHg.

Question 1

Which of the following statements is not true regarding the use of clonidine in the treatment of hypertension?

Accepted Answer

Increases LDL-cholesterol with prolonged use.

Answer

Reduces central sympathetic outflow.

Answer

Sedation and xerostomia are common side effects.

Answer

Can be combined with vasodilators.

Question 2

ACE inhibitors are contraindicated in all of the following conditions except:

Accepted Answer

Diabetes

Answer

Pregnancy

Answer

Bilateral renal artery stenosis

Answer

Renal failure

Question 3

All of the following statements regarding niacin-induced flushing and pruritus are true EXCEPT?

Accepted Answer

Warrants immediate stoppage of niacin.

Answer

Occurs due to release of prostaglandins by niacin.

Answer

More likely to occur if taken with ethanol-containing beverages.

Answer

Aspirin alleviates flushing in most patients.

Question 4

When treating hypertension chronically, orthostatic hypotension is maximum with which of the following medications?

Accepted Answer

Guanethidine

Answer

Clonidine

Answer

Prazosin

Answer

Propranolol

Question 5

A 55-year-old man presents with erectile dysfunction and is prescribed sildenafil. He reports a marked improvement in his ability to sustain an erection with this treatment. The action of which of the following vasoactive mediators would primarily be prolonged in this patient?

Accepted Answer

Nitric Oxide

Answer

Histamine

Answer

Endothelin-1

Answer

Prostacyclin

Question 6

Alirocumab and Evolocumab are classified as which of the following?

Accepted Answer

PCSK-9 inhibitors

Answer

NPGL1 inhibitors

Answer

Microsomal transport protein inhibitors

Answer

Lipoprotein lipase inhibitors

Question 7

In which condition is Digoxin indicated for Congestive Heart Failure (CHF)?

Accepted Answer

Atrial fibrillation with a high ventricular rate

Answer

Hypertrophic obstructive cardiomyopathy (HOCM)

Answer

High output failure

Answer

All of the above

Question 8

Amyl nitrate is used by which route?

Accepted Answer

Inhalation

Answer

Oral

Answer

Intravenous

Answer

Intramedullary

Question 9

In congestive cardiac failure, all of the following are used EXCEPT:

Accepted Answer

Trimetazidine

Answer

Spironolactone

Answer

Nitrates

Answer

Nesiritide

Question 10

Which of the following drugs reduces blood pressure primarily by directly decreasing heart rate?

Accepted Answer

Propranolol

Answer

Prazosin

Answer

Alpha methyl dopa

Answer

Nitroprusside sodium

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?